<div id="readability-page-1"><p>Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are presently  covering the stock, MarketBeat.com reports. One analyst  has rated the stock with a sell rating and five have issued  a buy rating on  the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $16.00.</p><div><p><span></span><span>Get <strong>Coya Therapeutics</strong> alerts:</span></p></div><ul><li>Doing Your Holiday Shopping? These Stocks Might Make Great Gifts</li></ul><p>A number of research firms recently weighed in on COYA. D. Boral Capital  reaffirmed a &#34;buy&#34; rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Monday. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. HC Wainwright  reaffirmed a &#34;buy&#34; rating on shares of Coya Therapeutics in a report on Monday, November 24th. Chardan Capital  reiterated a &#34;buy&#34; rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Friday, November 14th. Finally, Wall Street Zen raised shares of Coya Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th.</p><p><b>Check Out Our Latest Stock Report on COYA</b></p><h2>Coya Therapeutics Stock Down 1.9%</h2><ul><li>These biotechs targeting multiple neurodegenerative diseases</li></ul><p>Shares of COYA opened at $5.15 on Thursday. The company has a 50-day moving average price of $5.86 and a two-hundred day moving average price of $6.05. The stock has a market cap of $107.74 million, a price-to-earnings ratio of -4.64 and a beta of 0.25. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $8.29. </p><p>Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $3.70 million.  Equities research analysts expect that  Coya Therapeutics will post -1.15 EPS for the current fiscal year. </p><h2>Institutional Trading of Coya Therapeutics</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase &amp; Co. bought a new position in  Coya Therapeutics in the 3rd quarter worth approximately $28,000.  Lantern Wealth Advisors LLC acquired a new stake in shares of  Coya Therapeutics in the 3rd quarter valued at $66,000.  Northwestern Mutual Wealth Management Co. bought a new stake in shares of  Coya Therapeutics during the second quarter worth $119,000.  Prosperity Wealth Management Inc. raised its position in shares of  Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company's stock worth $136,000 after acquiring an additional 3,350 shares during the last quarter.  Finally, Jane Street Group LLC raised its position in shares of  Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after acquiring an additional 13,176 shares during the last quarter. Institutional investors and hedge funds own  39.75% of the company's stock. </p><h2>About Coya Therapeutics</h2> (Get Free Report)<p>Coya Therapeutics, Inc <span>NASDAQ: COYA<span></span></span> is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.  </p><p>Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Coya Therapeutics</li><li>You Still Think Silver’s a Joke? Watch What Happens Next.</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>A month before the crash</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>YDES Could Be 2026's Biotech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Coya Therapeutics Right Now?</h2><p>Before you consider Coya Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.</p><p>While Coya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

COYA

<p>Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of "Moderate Buy" from six brokerages. One analyst rated it as a sell, while five issued buy ratings. The average 12-month price target is $16.00. The stock opened at $5.15, with a market cap of $107.74 million. Coya reported a quarterly loss of ($0.10) per share, missing estimates. Institutional investors own 39.75% of the stock. Coya focuses on developing therapeutics for fibrotic diseases and cancer, with two lead programs in preclinical and clinical stages.</p>

Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages